Avidinox® for tissue targeted delivery of biotinylated cells

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue 1, 2012, Pages 239-246

  Nucera, E ^a   Nicoletti, C ^b   Chiapparino, C ^a   Pacello, M L ^a   D'Alessio, V ^a   Musaro A ^b   De Santis, Rita ^a  

^a Sigma Tau SpA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

AvidinOX; Biotinylated stem cells; Tissue targeted delivery

Indexed keywords

AVIDIN; BIOTIN; ALDEHYDE; ANTIBODY; AVIDIN ANTIBODY; AVIDIN DERIVATIVE; AVIDINOX; GREEN FLUORESCENT PROTEIN; PROTEIN DERIVATIVE; SCHIFF BASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BIOTINYLATION; C57BL 6 MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; TIBIALIS ANTERIOR MUSCLE; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CELL CULTURE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; BINDING AFFINITY; BONE MARROW CELL; CELL HOMING; CELL THERAPY; COMPLEX FORMATION; EVALUATION STUDY; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INFLAMMATION; TISSUE DISTRIBUTION; TISSUE SECTION; TISSUE TARGETED DELIVERY;

ANIMALS; AVIDIN; BIOTINYLATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MICE; MICE, INBRED C57BL; STEM CELL TRANSPLANTATION;

EID: 84861472179     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201202500126     Document Type: Article

References (23)

1. Brayfield CA, Marra KG, Rubin JP. Adipose tissue regeneration. Curr Stem Cell Res Ther 2010; 5:116-21.
2. Estrela C, Alencar AH, Kitten GT, Vencio EF, Gava E. Mesenchymal stem cells in the dental tissues: perspectives for tissue regeneration. Braz Dent J 2011; 22:91-8.
3. Hong D, Chen HX, Ge R, Li JC. Genetically engineered mesenchymal stem cells: The ongoing research for bone tissue engineering. Anat Rec (Hoboken) 2010; 293:531-7.
4. Shi C, Jia T, Mendez-Ferrer S, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 2011; 34:590-601.
5. Poulsom R, Alison MR, Forbes SJ, Wright NA. Adult stem cell plasticity. J Pathol 2002; 197:441-56.
6. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, Mavilio F. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279:1528-30. (Pubitemid 28217075)
7. Jin J, Zhao Y, Tan X, Guo C, Yang Z, Miao D. An improved transplantation strategy for mouse mesenchymal stem cells in an acute myocardial infarction model. PLoS One 2011; 6:e21005.
8. Brenner C, Franz WM. The use of stem cells for the repair of cardiac tissue in ischemic heart disease. Expert Rev Med Devices 2011; 8:209-25.
9. Engelmann MG, Franz WM. Stem cell therapy after myocardial infarction: ready for clinical application? Curr Opin Mol Ther 2006; 8:396-414. (Pubitemid 44566781)
10. Togel F, Westenfelder C. Adult bone marrow-derived stem cells for organ regeneration and repair. Dev Dyn 2007; 236:3321-31. (Pubitemid 350276389)
11. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009; 4:206-16.
12. Carosio S, Berardinelli MG, Aucello M, Musaro A. Impact of ageing on muscle cell regeneration. Ageing Res Rev 2011; 10:35-42.
13. Musaro A, Giacinti C, Borsellino G, et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci USA 2004; 101:1206-10. (Pubitemid 38182667)
14. Ferrari G, Stornaiuolo A, Mavilio F. Failure to correct murine muscular dystrophy. Nature 2001; 441:1014-15. (Pubitemid 32612316)
15. De Santis R, Albertoni C, Rosi A, et al. OXavidin for tissue targeting biotinylated therapeutics. J Biomed Biotechnol 2010; doi: 10.1155/2009/921434.
16. Verdoliva A, Bellofiore P, Rivieccio V, et al. Biochemical and biological characterization of a new HABA-assisted oxidized avidin with enhanced tissue binding properties. J Biol Chem 2010; 286(12):9090-9.
17. De Santis R, Leoni B, Rosi A, et al. AvidinOX™ for highly efficient tissue pre-targeted radionuclide therapy. Cancer Biother Radiopharmaceuticals 2010; 25(2):143-8.
18. De Santis R, Anastasi AM, Pelliccia A, et al. Chemical linkage to injected tissues is a distinctive property of oxidized avidin. PLoS One 2011; 6(6):e21075 Epub ahead of print
19. Petronzelli F, Pelliccia A, Anastasi AM, et al. Therapeutic use of avidin is not hampered by anti-avidin antibodies in humans. Cancer Biother Radiopharm 2010; 25:563-70.
20. Petronzelli F, Anastasi AM, Pelliccia A, et al. Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin. Basic Clin Pharmacol Toxicol 2011; doi:10.1111/j.1742- 7843.2011.00701.x.
21. Douglas MR, Morrison KE, Salmon M, Buckley CD. Why does inflammation persist: a dominant role for the stromal microenvironment? Expert Rev Mol Med 2002; 4:1-18.
22. Sarkar D, Zhao W, Gupta A, Loh WL, Karnik R, Karp JM. Cell surface engineering of mesenchymal stem cells. Methods Mol Biol 2011; 698:505-23.
23. Mitchell KJ, Pannerec A, Cadot B, Parlakian A, Besson V, Gomes ER, Marazzi G, Sassoon DA. Identification and characterization of a non-satellite cell muscle resident progenitor during postnatal development. Nat Cell Biol 2010; 12:257-66.